Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Andrx Altocor Sales Force Expands 50%; Generic Prilosec Charge Is $41 Mil.

  • News

Executive Summary

Andrx plans to increase its sales force to 450 reps to support the cholesterol agent Altocor, CEO Richard Lane said during an Oct. 31 conference call

You may also be interested in...



Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm

Schwarz is expected to launch generic omeprazole by the end of year after FDA approval Nov. 1

Schwarz Generic Prilosec Clears FDA After Deal With Andrx, Genpharm

Schwarz is expected to launch generic omeprazole by the end of year after FDA approval Nov. 1

Generic Prilosec Launch Awaits Negotiations Between Andrx And Schwarz

Andrx is considering licensing its 180-day exclusivity for generic omeprazole to Schwarz Pharma following an Oct. 11 federal court ruling that Andrx' product infringes AstraZeneca's Prilosec patents, but Schwarz' does not

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS040708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By